Holen Sie sich die Stockscreener-App
7.367
4.04%
-0.313
Schlusskurs vom Vortag:
$7.68
Offen:
$7.6
24-Stunden-Volumen:
303.28K
Relative Volume:
0.22
Marktkapitalisierung:
$537.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-2.601
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
-0.27%
1M Leistung:
-29.41%
6M Leistung:
+88.97%
1J Leistung:
+31.37%
1-Tages-Spanne:
$7.31
$7.83
1-Wochen-Bereich:
$7.02
$7.84
52-Wochen-Spanne:
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
7.36 | 560.54M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.41 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.53 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.01 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.15 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Retail Surge: Does Lexeo Therapeutics Inc have declining or rising EPS2025 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn
Fund Flows: What is GNSRTs debt to equity ratioWeekly Trend Summary & Precise Trade Entry Recommendations - baoquankhu1.vn
Market Wrap: Can Lexeo Therapeutics Inc ride the EV waveJuly 2025 Setups & Daily Technical Forecast Reports - baoquankhu1.vn
Technical Analysis: Is Lexeo Therapeutics Inc subject to activist investor interestJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Block Trades: Does Lexeo Therapeutics Inc have a sustainable dividend2025 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Does Lexeo Therapeutics Inc have a sustainable dividendPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Aug Update: Is SLAB subject to activist investor interestWeekly Investment Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug Decliners: Will Lexeo Therapeutics Inc outperform its industry peersEarnings Risk Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Price Action: Will Lexeo Therapeutics Inc outperform its industry peersAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
LXEO: Cardiac gene therapy programs show strong efficacy, safety, and commercial readiness - TradingView — Track All Markets
Heart-disease gene therapy race heating up as Lexeo posts data - BioWorld MedTech
Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 6.5%Should You Sell? - MarketBeat
Day Trade: Will Lexeo Therapeutics Inc stock outperform growth indexesJuly 2025 Setups & Safe Entry Point Alerts - Bộ Nội Vụ
H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com Canada
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Aug Intraday: Will Lexeo Therapeutics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Stepwise Trade Signal Guides - Bộ Nội Vụ
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright - TipRanks
Lexeo’s gene therapy shows promising results for heart condition By Investing.com - Investing.com Nigeria
Update Recap: Is Lexeo Therapeutics Inc forming a bullish divergenceDay Trade & Safe Capital Growth Plans - baoquankhu1.vn
Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap DownHere's What Happened - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 - TradingView — Track All Markets
Lexeo Therapeutics stock falls after PKP2 gene therapy data By Investing.com - Investing.com Canada
Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com
Lexeo’s gene therapy shows promising results for heart condition - Investing.com
Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy - The Manila Times
Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 9% – Here’s Why - Defense World
Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 EndofMonth & AI Forecast Swing Trade Picks - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE) - The Globe and Mail
Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9%Still a Buy? - MarketBeat
Why Lexeo Therapeutics Inc. stock remains a top recommendationJuly 2025 WrapUp & Safe Capital Preservation Plans - Улправда
Why Lexeo Therapeutics Inc. stock appeals to analystsWeekly Risk Report & Advanced Technical Analysis Signals - Улправда
Why Lexeo Therapeutics Inc. stock attracts global investors2025 Market Overview & Fast Entry High Yield Stock Tips - ulpravda.ru
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Explore Targeted Cardiac Delivery of Aav Gene Therapy - marketscreener.com
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology - Quiver Quantitative
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy - GlobeNewswire
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5%What's Next? - MarketBeat
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) and Wellgistics Health (NASDAQ:WGRX) - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 3.5%Here's What Happened - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Insider Monkey
Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):